Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

Published:2012-11-21 Issue:12 Volume:28 Page:1921-1931
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Vazquez José A.¹,González Patzán Luis Demetrio²,Stricklin David³,Duttaroy Dipesh D.⁴,Kreidly Zouheir⁵,Lipka Joy⁶,Sable Carole⁶

Affiliation:

1. Division of Infectious Diseases, Henry Ford Hospital Detroit, MIUSA

2. Centro Médico Militar, Guatemala CityGuatemala

3. Four Rivers Clinical Research Inc. Paducah, KYUSA

4. Medical College Baroda and Sir Sayajirao General Hospital VadodaraIndia

5. Makassed General Hospital BeirutLebanon

6. AstraZeneca Wilmington, DEUSA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2012.748653

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of carbapenems and alternative antimicrobials for treating complicated urinary tract infections caused by third-generation cephalosporin-resistant gram-negative bacteria: A systematic review and meta-analysis of randomised controlled trials;Journal of Infection and Chemotherapy;2024-11

2. Estimating the value of new antibiotic treatment strategies in Zhejiang province, China: cost-effectiveness analysis based on a validated dynamic model;BMJ Open;2024-08

3. Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis;Infection;2024-05-13

4. Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review;Frontiers in Microbiology;2024-05-10

5. Exploring the World of ß-Lactamase Inhibitors;Advances in Medical Technologies and Clinical Practice;2024-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3